Nivolumab In Advanced Lung Cancer: Indication Of Major Added Benefit
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already…